We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
+22.19%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.06B
AUM Growth
+$94.9M
(+4.8%)
Cap. Flow
-$114M
Cap. Flow
% of AUM
-5.52%
Top 10 Holdings %
Top 10 Hldgs %
74.94%
Holding
37
New
2
Increased
3
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$43.1M |
| 2 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$20.9M |
| 3 |
Lexicon Pharmaceuticals
LXRX
|
+$5.76M |
| 4 |
TRVN
Trevena, Inc.
TRVN
|
+$5.3M |
| 5 |
AGRX
Agile Therapeutics
AGRX
|
+$635K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Groupon
GRPN
|
+$72.3M |
| 2 |
CVT
CVENT, INC.
CVT
|
+$52.3M |
| 3 |
Ardelyx
ARDX
|
+$23.2M |
| 4 |
Nektar Therapeutics
NKTR
|
+$22M |
| 5 |
ALIM
Alimera Sciences
ALIM
|
+$12.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.78% |
| 2 | Communication Services | 18.33% |
| 3 | Technology | 12.38% |
| 4 | Consumer Discretionary | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gyre Therapeutics
GYRE
$641M
| $12M | 0.58% |
5,799
| – | – |
|
|
VIRX
27
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $11.9M | 0.58% |
22,187
| – | – |
|
28
Aurinia Pharmaceuticals
AUPH
$1.91B
| $9.27M | 0.45% |
2,546,843
| – | – |
|
|
DZSI
29
DELISTED
DZS Inc. Common Stock
DZSI
| $8.46M | 0.41% |
956,258
| – | – |
|
30
Rigel Pharmaceuticals
RIGL
$681M
| $7.36M | 0.36% |
324,315
| – | – |
|
|
PRTK
31
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $6.7M | 0.33% |
173,894
-2
| -0% | -$48 |
|
32
Exelixis
EXEL
$13.3B
| $3.18M | 0.15% |
2,207,000
| – | – |
|
|
ARQL
33
DELISTED
Arqule Inc
ARQL
| $3.08M | 0.15% |
2,520,316
| – | – |
|
|
AGRX
34
DELISTED
Agile Therapeutics
AGRX
| $802K | 0.04% |
65
+50
| +333% | +$635K |
|
|
NURO
35
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
| $112K | 0.01% |
22
| – | – |
|
|
36
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-121,707
| Closed | -$22M |
|
|
ALIM
37
DELISTED
Alimera Sciences
ALIM
| – | – |
-150,376
| Closed | -$12.2M |
|
Similar funds
NM
SLF
CCIA
SW
CGH
PWP
CIP
GD
NEA Management Company's Q4 2014 Portfolio in Review
As of Q4 2014, NEA Management Company held 37 positions worth $2.06B, up 4.8% from $1.97B the previous quarter. Its ten largest holdings account for 75% of the portfolio.
NEA Management Company withdrew a net $114M in Q4 2014, closing 2 positions and reducing 5 holdings. Its most notable exit was Nektar Therapeutics, an estimated $22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 48% a quarter earlier, followed by Communication Services and Technology.
Against the trend, NEA Management Company opened a new position in NEVRO CORP. worth $53M.
- NEA Management Company's largest Q4 2014 buy was NEVRO CORP.: 1,369,899 shares worth $53M.
- NEA Management Company added most to Lexicon Pharmaceuticals in Q4 2014, an estimated $5.76M increase.
- NEA Management Company's biggest Q4 2014 reduction was Groupon, cutting an estimated $72.3M.
- NEA Management Company fully exited Nektar Therapeutics in Q4 2014, selling an estimated $22M.
- NEA Management Company's ten largest holdings make up 75% of its $2.06B portfolio in Q4 2014.
- NEA Management Company opened 2 new positions and closed 2 in Q4 2014.
- NEA Management Company's portfolio value rose 4.8% quarter-over-quarter to $2.06B.
Based on NEA Management Company's 13F filing for Q4 2014, filed 26 Jan 2015.